Ocular Therapeutix (FRA:0OT) 3-Year Dividend Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ocular Therapeutix 3-Year Dividend Growth Rate?

Ocular Therapeutix's Dividends per Share for the three months ended in Mar. 2024 was €0.00.

The historical rank and industry rank for Ocular Therapeutix's 3-Year Dividend Growth Rate or its related term are showing as below:

FRA:0OT's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.15
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Ocular Therapeutix's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Ocular Therapeutix's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Ocular Therapeutix's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Ocular Therapeutix's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocular Therapeutix's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's 3-Year Dividend Growth Rate falls into.

Ocular Therapeutix 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Ocular Therapeutix (FRA:0OT) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Ocular Therapeutix's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-0.22
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocular Therapeutix 3-Year Dividend Growth Rate Related Terms>

Ocular Therapeutix (FRA:0OT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (FRA:0OT) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

OCUL:USA 0OT:Germany

Address

24 Crosby Drive, Bedford, MA, USA, 01730

Website

https://www.ocutx.com

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Ocular Therapeutix (FRA:0OT) Headlines

No Headlines